Climb Bio, Inc. (CLYM) vs OmniAb, Inc. (OABI)
Climb Bio, Inc. and OmniAb, Inc. are both Biotechnology companies. Climb Bio, Inc. and OmniAb, Inc. are of similar size ($697.9M and $682.9M). Climb Bio, Inc. has the higher net margin (0.00% vs −115.1%) and the lower return on invested capital (−71.7% vs −14.5%). Across the 12 metrics below, Climb Bio, Inc. leads on 6 and OmniAb, Inc. on 6.
Valuation
Profitability
| Metric | CLYM | OABI | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 98.28% | 65.16% |
| Operating margin | 0.00% | (125.78%) | 0.00% |
| Net margin | 0.00% | (115.12%) | 0.00% |
| Free cash flow margin | 0.00% | (47.17%) | 0.00% |
| Return on equity | (27.10%) | (16.95%) | (57.72%) |
| Return on assets | (26.27%) | (15.11%) | (49.22%) |
| Return on invested capital | (71.73%) | (14.52%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack